Does Blue Cross Blue Shield of Massachusetts Cover Farxiga?

How BCBSMA Formulary Placement Works for Farxiga

Blue Cross Blue Shield of Massachusetts organizes prescription drugs into tiers that determine patient cost-sharing. Farxiga typically sits on Tier 2 (preferred brand) in many commercial HMO and PPO plans, though certain plan designs place it on Tier 3 (non-preferred brand). The tier assignment directly controls your copay or coinsurance percentage.

BCBSMA maintains separate formularies for its commercial plans, Medicare Advantage (Blue MedicareRx), and MassHealth-associated managed care products. Each formulary undergoes annual review by a Pharmacy and Therapeutics (P&T) committee. The SGLT2 inhibitor class, which includes Farxiga, Jardiance (empagliflozin), and Invokana (canagliflozin), has expanded across formularies following cardiovascular and renal outcome data. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74; 95% CI, 0.65-0.85) in patients with heart failure and reduced ejection fraction [1]. That trial's results pushed many insurers, including BCBSMA, to broaden access beyond diabetes-only coverage.

Your specific plan documents, accessible through the BCBSMA member portal or your Summary of Benefits and Coverage (SBC), will confirm which tier applies. If Farxiga appears on a higher tier than expected, your prescriber can request a tier exception.

Prior Authorization Requirements

Most BCBSMA plans require prior authorization (PA) before dispensing Farxiga. The PA process verifies that the prescription meets the insurer's medical necessity criteria, and approval typically takes 24 to 72 hours for standard requests.

For type 2 diabetes, BCBSMA commonly requires documentation that the patient has tried or cannot tolerate metformin, unless metformin is contraindicated. This step-therapy requirement reflects the American Diabetes Association (ADA) Standards of Care, which recommend metformin as first-line pharmacotherapy for most adults with type 2 diabetes [2]. For heart failure and chronic kidney disease (CKD) indications, PA criteria differ. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained decline in eGFR of 50% or greater, end-stage kidney disease, or renal/cardiovascular death by 39% versus placebo (HR 0.61; 95% CI, 0.51-0.72), regardless of diabetes status [3]. Given these data, some BCBSMA plans waive the metformin step-therapy requirement for CKD or heart failure indications.

Your prescriber's office will submit the PA request. They need to include the diagnosis, prior medication trials, relevant lab values (HbA1c, eGFR, ejection fraction), and the specific FDA-approved indication being targeted. Denials can be appealed through BCBSMA's standard appeals process within 60 days.

What You Can Expect to Pay Out of Pocket

Your actual cost for Farxiga under BCBSMA depends on several variables: plan type, tier placement, deductible phase, and whether you use a preferred pharmacy. Without insurance, the retail price of Farxiga runs approximately $550 to $620 for a 30-day supply. With BCBSMA commercial coverage, copays typically range from $35 to $90 per month after the deductible is met.

High-deductible health plans (HDHPs) paired with health savings accounts (HSAs) require patients to pay the full negotiated price until the deductible is satisfied. For a BCBSMA HDHP member with a $2,000 individual deductible, this could mean several months of full-price fills at the beginning of the plan year. Members in this situation should consider the AstraZeneca Farxiga Savings Card, which can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients, with a maximum annual benefit that varies by program year [4].

Medicare Advantage members under Blue MedicareRx plans face different cost-sharing structures. During the initial coverage phase, Farxiga copays for Medicare Part D beneficiaries typically fall between $42 and $100 per month for Tier 3 drugs. After entering the coverage gap (the "donut hole"), members pay 25% of the negotiated price for brand-name drugs under the current Medicare Part D benefit design. The Inflation Reduction Act capped total out-of-pocket Part D spending at $2,000 annually beginning in 2025, which meaningfully reduces exposure for patients taking multiple branded medications [5].

Farxiga's FDA-Approved Indications and Why They Matter for Coverage

The breadth of Farxiga's FDA label directly affects insurance coverage decisions. Farxiga holds three distinct FDA-approved indications: type 2 diabetes mellitus (approved 2014), heart failure with reduced and preserved ejection fraction (approved 2020, expanded 2023), and chronic kidney disease at risk of progression (approved 2021) [4].

Each indication carries its own clinical evidence base, and BCBSMA may apply different coverage criteria depending on which condition your prescriber documents. A prescription written for type 2 diabetes follows a different PA pathway than one written for heart failure. The DELIVER trial (N=6,263) extended dapagliflozin's heart failure evidence to patients with mildly reduced or preserved ejection fraction (LVEF >40%), showing a 18% reduction in the composite of cardiovascular death or worsening heart failure (HR 0.82; 95% CI, 0.73-0.92) [6].

This matters practically. If your prescriber writes for Farxiga with a primary diagnosis of heart failure (ICD-10 code I50.x) rather than type 2 diabetes (E11.x), the PA requirements may be less restrictive because step therapy through metformin would not apply. Confirm with your prescriber which diagnosis code they are using on the prescription and PA submission.

How Farxiga Compares to Other Covered SGLT2 Inhibitors on BCBSMA

BCBSMA formularies typically include multiple SGLT2 inhibitors, and your cost may vary significantly depending on which one your prescriber selects. Jardiance (empagliflozin) often shares the same formulary tier as Farxiga on BCBSMA commercial plans, but preferred status can shift during annual formulary updates based on rebate negotiations between AstraZeneca, Boehringer Ingelheim/Eli Lilly, and the plan's pharmacy benefit manager (PBM).

The EMPA-REG OUTCOME trial (N=7,020) established empagliflozin's cardiovascular benefit in type 2 diabetes patients with established cardiovascular disease, demonstrating a 38% relative risk reduction in cardiovascular death (HR 0.62; 95% CI, 0.49-0.77) [7]. The ADA's 2024 Standards of Care recommend SGLT2 inhibitors with proven cardiovascular or renal benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD, without specifying a preferred agent within the class [2].

If BCBSMA places one SGLT2 inhibitor on a lower (cheaper) tier than another, switching to the preferred agent within the same class is a reasonable option to discuss with your prescriber. Both dapagliflozin and empagliflozin carry class-level evidence for cardiorenal protection, and the 2022 AHA/ACC/HFSA heart failure guideline gives a Class I recommendation to SGLT2 inhibitors as a group for heart failure management [8].

Invokana (canagliflozin) is a third option, though some BCBSMA plans have moved it to a higher tier or removed it from formulary following the CANVAS trial's signal for increased amputation risk, a finding not replicated with dapagliflozin or empagliflozin [9].

Steps to Verify Your Specific BCBSMA Coverage

Checking your Farxiga coverage requires a few specific actions, and each step gives you different information.

First, log into the BCBSMA member portal at bluecrossma.org or call the member services number on the back of your insurance card. Use the formulary search tool to look up "dapagliflozin" or "Farxiga" and note the tier, PA requirements, quantity limits, and any step-therapy criteria listed for your specific plan.

Second, ask your prescriber's office to run a real-time pharmacy benefit check (e-prescribing eligibility verification) before sending the prescription. This electronic check returns your plan's formulary status, estimated copay, and PA requirements within seconds. It is more accurate than the general formulary lookup because it reflects your individual benefit design and deductible status.

Third, contact the dispensing pharmacy. Pharmacists can process a test claim to determine the exact adjudicated price before you commit to filling the prescription. If the price is higher than expected, the pharmacist can also check whether a 90-day mail-order fill through BCBSMA's preferred mail-order pharmacy would lower the per-unit cost. Many BCBSMA plans offer a cost advantage for 90-day supplies through mail order, often pricing three months of medication at two copays instead of three.

What to Do If BCBSMA Denies Farxiga Coverage

A coverage denial is not the final word. BCBSMA provides a structured appeals process, and success rates for prescription drug appeals are meaningful. Across commercial insurers nationally, approximately 40-60% of prescription drug prior authorization denials are overturned on appeal when clinical documentation supports medical necessity [10].

If denied, your prescriber should submit a formal appeal letter including: the specific FDA-approved indication, documentation of prior medication trials and their outcomes, relevant clinical data (HbA1c, eGFR, LVEF, UACR as appropriate), and citations to clinical guidelines supporting Farxiga use. The ADA Standards of Care, KDIGO 2024 CKD guideline, and AHA/ACC/HFSA heart failure guideline all provide strong support for SGLT2 inhibitor use in their respective indications [2][8][11].

BCBSMA must respond to standard appeals within 30 days for non-urgent requests and 72 hours for urgent/expedited appeals. If the internal appeal is denied, Massachusetts law allows an external review through the state's Office of Patient Protection. This independent review is binding on the insurer.

Alternative Cost-Reduction Strategies

Beyond standard insurance coverage, several pathways can reduce your Farxiga costs.

AstraZeneca's Farxiga Savings Card is the first option for commercially insured patients. The program typically reduces copays to $0 for eligible patients, with an annual maximum benefit. Medicare, Medicaid, and government-insured patients are not eligible for manufacturer copay cards under federal anti-kickback statute regulations [4].

For Medicare patients, the Extra Help (Low-Income Subsidy) program through the Social Security Administration can reduce Part D copays to $0-$11.20 per prescription for qualifying individuals. Income limits for full Extra Help in 2026 are approximately 150% of the federal poverty level [5].

Patient assistance programs (PAPs) through AstraZeneca (AZ&Me) provide free Farxiga to uninsured or underinsured patients who meet income eligibility criteria, typically set at 400% of the federal poverty level or below.

If all else fails and cost remains prohibitive, the SGLT2 inhibitor class offers clinical flexibility. Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine and a principal investigator in multiple SGLT2 inhibitor trials, has noted: "The cardiovascular and renal benefits of SGLT2 inhibitors appear to be a class effect. If one agent is inaccessible due to cost or coverage, switching to another SGLT2 inhibitor with similar outcome data is clinically reasonable."

The 2024 KDIGO guideline for CKD management recommends SGLT2 inhibitors for patients with CKD and eGFR 20-45 mL/min/1.73m², with or without diabetes, representing a population where Farxiga's DAPA-CKD data provide the strongest evidence base [11].

Massachusetts residents should also check the Health Safety Net program for those who are uninsured or underinsured and have incomes at or below 300% of the federal poverty level. This state-specific program can cover prescription drug costs that other programs do not.

Your prescriber can check real-time formulary alternatives by running a benefit verification at the point of prescribing, confirming the lowest-cost SGLT2 inhibitor on your specific BCBSMA plan before you fill the prescription.